bluebird bio Announces Interim Phase 1 Dose Escalation Data for its Anti-BCMA CAR T Product Candidate in Patients with Relapsed/Refractory Multiple Myeloma

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. DFTX
6. GOOGL
7. APGE
8. HOOD
9. MU
10. IBM

Go back to bluebird bio Announces Interim Phase 1 Dose Escalation Data for its Anti-BCMA CAR T Product Candidate in Patients with Relapsed/Refractory Multiple Myeloma

BTIG Affirms bluebird bio (BLUE) at 'Buy' Following bb2121 Phase 1 Data in r/r Multiple Myeloma

December 1, 2016 7:51 AM EST

BTIG affirms bluebird bio, Inc. (Nasdaq: BLUE) with a Buy rating and $83 price target following strong results from bb2121 Phase 1 in r/r multiple myeloma.

Analyst Dane Leone commented, The... More

bluebird bio (BLUE) PT Raised 10% at Jefferies Following 'Impressive' Initial BCMA CAR-T Ph1 Data

December 1, 2016 7:47 AM EST

Jefferies analyst Gena Wang reiterated a Buy rating and lifted her price target on bluebird bio (NASDAQ: BLUE) to $88.00 (from $80.00) following 'impressive' initial BCMA CAR-T Ph1 data at ENA.

Wang commented, "BLUE/CELGs anti-BCMA CAR T cells (bb2121) showed promising initial... More

bluebird bio (BLUE) PT Raised to $83 at BMO as bb2121 Shows Promising Efficacy, Clean Safety

December 1, 2016 6:18 AM EST

BMO Capital analyst Matthew Luchini raised his price target on bluebird bio (NASDAQ: BLUE) to $83.00 (from $61.00) as bb2121 shows promising efficacy and clean saftey. The firm maintained a Market Perform rating.

Luchini commented, "We expect BLUE to open higher following... More